SCHEMBL2178224

SCHEMBL2178224

Cc1cccc(NC(=O)Nc2ccc(-c3ccc4c(c3)CN([C@H](C(=O)O)C(C)C)C4=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.52
CSF1R P07333 2/20 0.47
FLT1 P17948 2/20 0.47
FLT3 P36888 2/20 0.47
KDR P35968 4/20 0.46
PLK4 O00444 1/20 0.46
AURKA O14965 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
RET P07949 1/20 0.46
MET P08581 1/20 0.46
PIM1 P11309 1/20 0.46
RPS6KB1 P23443 1/20 0.46
EPHA2 P29317 1/20 0.46
FLT4 P35916 1/20 0.46
BLK P51451 1/20 0.46
CSNK2A1 P68400 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178233 1.00 DGAT1 (0.52) DGAT1CSF1RFLT1FLT3KDR
SCHEMBL2177490 0.93 KDR (0.50) DGAT1CSF1RFLT1FLT3KDR
SCHEMBL2179963 0.93 KDR (0.50) DGAT1CSF1RFLT1FLT3KDR
SCHEMBL2181226 0.92 LMNA (0.51) DGAT1SDCBPSDC2LMNATP53
SCHEMBL2179718 0.92 LMNA (0.51) DGAT1SDCBPSDC2LMNATP53
SCHEMBL2177097 0.91 SDCBP (0.48) DGAT1SDCBPSDC2LMNATP53
SCHEMBL2177104 0.91 SDCBP (0.48) DGAT1SDCBPSDC2LMNATP53
SCHEMBL2179339 0.90 DGAT1 (0.52) DGAT1KDRAURKAMAP4K4LCK
SCHEMBL2180590 0.90 DGAT1 (0.52) DGAT1KDRAURKAMAP4K4LCK
SCHEMBL2181456 0.88 DGAT1 (0.53) DGAT1KDRSDCBPSDC2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885CSF1R 3299/4885FLT1 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.